The Woodlands, Texas, June 21, 2024 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that, following multiple interactions with and recent feedback from the U.S. Food and Drug Administration (FDA), it has resubmitted its New Drug…Original Article
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
